AnGes Inc (AMGXF)
0.3353
0.00 (0.00%)
USD |
OTCM |
May 20, 16:00
AnGes Enterprise Value: 59.01M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 59.01M |
| May 17, 2024 | 59.01M |
| May 16, 2024 | 59.01M |
| May 15, 2024 | 59.01M |
| May 14, 2024 | 59.01M |
| May 13, 2024 | 53.52M |
| May 10, 2024 | 53.52M |
| May 09, 2024 | 53.52M |
| May 08, 2024 | 53.52M |
| May 07, 2024 | 53.52M |
| May 06, 2024 | 53.52M |
| May 03, 2024 | 53.52M |
| May 02, 2024 | 53.52M |
| May 01, 2024 | 53.52M |
| April 30, 2024 | 53.52M |
| April 29, 2024 | 53.52M |
| April 26, 2024 | 53.52M |
| April 25, 2024 | 53.52M |
| April 24, 2024 | 61.11M |
| April 23, 2024 | 61.11M |
| April 22, 2024 | 61.11M |
| April 19, 2024 | 61.11M |
| April 18, 2024 | 61.11M |
| April 17, 2024 | 61.11M |
| April 16, 2024 | 79.25M |
| Date | Value |
|---|---|
| April 15, 2024 | 79.25M |
| April 12, 2024 | 79.25M |
| April 11, 2024 | 79.25M |
| April 10, 2024 | 79.25M |
| April 09, 2024 | 79.25M |
| April 08, 2024 | 79.25M |
| April 05, 2024 | 79.25M |
| April 04, 2024 | 79.25M |
| April 03, 2024 | 79.25M |
| April 02, 2024 | 79.25M |
| April 01, 2024 | 79.25M |
| March 31, 2024 | 79.25M |
| March 28, 2024 | 62.41M |
| March 27, 2024 | 62.41M |
| March 26, 2024 | 62.41M |
| March 25, 2024 | 62.41M |
| March 22, 2024 | 62.41M |
| March 21, 2024 | 62.41M |
| March 20, 2024 | 62.41M |
| March 19, 2024 | 62.41M |
| March 18, 2024 | 62.41M |
| March 15, 2024 | 62.41M |
| March 14, 2024 | 62.41M |
| March 13, 2024 | 62.41M |
| March 12, 2024 | 62.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
53.52M
Minimum
Apr 25 2024
2.434B
Maximum
Jun 17 2020
455.12M
Average
105.22M
Median
Nov 11 2022
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 70.56B |
| Nxera Pharma Co Ltd | 1.009B |
| PeptiDream Inc | 1.517B |
| Healios KK | 62.31M |
| SanBio Co Ltd | 238.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.29M |
| Revenue (Quarterly) | 0.7651M |
| Total Expenses (Quarterly) | 17.45M |
| EPS Diluted (Quarterly) | -0.0616 |
| Gross Profit Margin (Quarterly) | 63.05% |
| Profit Margin (Quarterly) | -1.61K% |
| Earnings Yield | -67.77% |
| Normalized Earnings Yield | -48.53 |